Drug DevelopmentPreliminary dose-escalation results for GBM remain on track and progress with COVID-19 and flu Phase 2 trials continues, showing promise in CureVac's pipeline.
Financial PerformanceThe company plans to streamline the organization, reducing its workforce to extend its operating runway, indicating improved financial sustainability.
Strategic PartnershipsCollaboration with MD Anderson for antigen discovery and vaccine development, with CureVac retaining exclusive rights, enhances the company's research capabilities.